Africa: Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results
Twice-yearly injectable lenacapavir has continued to demonstrate exceptional protection against HIV infection. Twice-yearly injectable lenacapavir continued to provide strong protection against HIV in two landmark clinical trials, with updated data showing almost no new infections, high adherence and no new safety concerns. Researchers said updated findings from the PURPOSE-1 and PURPOSE-2 studies showed the long-acting drug remained highly effective, safe and well accepted by participants during extended follow-up.
- ▪Twice-yearly injectable lenacapavir has continued to demonstrate exceptional protection against HIV infection.
- ▪Twice-yearly injectable lenacapavir continued to provide strong protection against HIV in two landmark clinical trials, with updated data showing almost no new infections, high adherence and no new safety concerns.
- ▪Researchers said updated findings from the PURPOSE-1 and PURPOSE-2 studies showed the long-acting drug remained highly effective, safe and well accepted by participants during extended follow-up.
AllAfrica files mainly under world. We currently carry 87 of its stories.
Opening excerpt (first ~120 words) tap to expand
Twice-yearly injectable lenacapavir has continued to demonstrate exceptional protection against HIV infection. Twice-yearly injectable lenacapavir continued to provide strong protection against HIV in two landmark clinical trials, with updated data showing almost no new infections, high adherence and no new safety concerns. Researchers said updated findings from the PURPOSE-1 and PURPOSE-2 studies showed the long-acting drug remained highly effective, safe and well accepted by participants during extended follow-up. This raises hope that the long-acting drug could transform HIV prevention if rolled out equitably.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at AllAfrica.
Discussion
0 commentsMore from AllAfrica
